Advances in biology of multiple myeloma: clinical applications - PubMed (original) (raw)
Review
. 2004 Aug 1;104(3):607-18.
doi: 10.1182/blood-2004-01-0037. Epub 2004 Apr 15.
Affiliations
- PMID: 15090448
- DOI: 10.1182/blood-2004-01-0037
Free article
Review
Advances in biology of multiple myeloma: clinical applications
Teru Hideshima et al. Blood. 2004.
Free article
Abstract
There appear to be 2 pathways involved in the early pathogenesis of premalignant monoclonal gammopathy of undetermined significance (MGUS) and malignant multiple myeloma (MM) tumors. Nearly half of these tumors are nonhyperdiploid and mostly have immunoglobulin H (IgH) translocations that involve 5 recurrent chromosomal loci, including 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (fibroblast growth factor receptor 3 [FGFR3] and multiple myeloma SET domain [MMSET]), 16q23 (c-maf), and 20q11 (mafB). The remaining tumors are hyperdiploid and contain multiple trisomies involving chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, but infrequently have IgH translocations involving the 5 recurrent loci. Dysregulated expression of cyclin D1, D2, or D3 appears to occur as an early event in virtually all of these tumors. This may render the cells more susceptible to proliferative stimuli, resulting in selective expansion as a result of interaction with bone marrow stromal cells that produce interleukin-6 (IL-6) and other cytokines. There are 5 proposed tumor groups, defined by IgH translocations and/or cyclin D expression, that appear to have differences in biologic properties, including interaction with stromal cells, prognosis, and response to specific therapies. Delineation of the mechanisms mediating MM cell proliferation, survival, and migration in the bone marrow (BM) microenvironment may both enhance understanding of pathogenesis and provide the framework for identification and validation of novel molecular targets.
Similar articles
- Molecular pathogenesis and a consequent classification of multiple myeloma.
Bergsagel PL, Kuehl WM. Bergsagel PL, et al. J Clin Oncol. 2005 Sep 10;23(26):6333-8. doi: 10.1200/JCO.2005.05.021. J Clin Oncol. 2005. PMID: 16155016 Review. - Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Bergsagel PL, et al. Blood. 2005 Jul 1;106(1):296-303. doi: 10.1182/blood-2005-01-0034. Epub 2005 Mar 8. Blood. 2005. PMID: 15755896 Free PMC article. - Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.
Bergsagel PL, Kuehl WM. Bergsagel PL, et al. Immunol Rev. 2003 Aug;194:96-104. doi: 10.1034/j.1600-065x.2003.00052.x. Immunol Rev. 2003. PMID: 12846810 Review. - Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
Shaughnessy J Jr, Gabrea A, Qi Y, Brents L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL, Kuehl M. Shaughnessy J Jr, et al. Blood. 2001 Jul 1;98(1):217-23. doi: 10.1182/blood.v98.1.217. Blood. 2001. PMID: 11418483 - Chromosome translocations in multiple myeloma.
Bergsagel PL, Kuehl WM. Bergsagel PL, et al. Oncogene. 2001 Sep 10;20(40):5611-22. doi: 10.1038/sj.onc.1204641. Oncogene. 2001. PMID: 11607813 Review.
Cited by
- Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma.
Aoki Y, Nojima M, Suzuki H, Yasui H, Maruyama R, Yamamoto E, Ashida M, Itagaki M, Asaoku H, Ikeda H, Hayashi T, Imai K, Mori M, Tokino T, Ishida T, Toyota M, Shinomura Y. Aoki Y, et al. Genome Med. 2012 Dec 22;4(12):101. doi: 10.1186/gm402. eCollection 2012. Genome Med. 2012. PMID: 23259664 Free PMC article. - In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.
Di Martino MT, Gullà A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, Tassone P. Di Martino MT, et al. Oncotarget. 2013 Feb;4(2):242-55. doi: 10.18632/oncotarget.820. Oncotarget. 2013. PMID: 23479461 Free PMC article. - AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
Santo L, Vallet S, Hideshima T, Cirstea D, Ikeda H, Pozzi S, Patel K, Okawa Y, Gorgun G, Perrone G, Calabrese E, Yule M, Squires M, Ladetto M, Boccadoro M, Richardson PG, Munshi NC, Anderson KC, Raje N. Santo L, et al. Oncogene. 2010 Apr 22;29(16):2325-36. doi: 10.1038/onc.2009.510. Epub 2010 Jan 25. Oncogene. 2010. PMID: 20101221 Free PMC article. - Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC. Tai YT, et al. Blood. 2007 Sep 1;110(5):1656-63. doi: 10.1182/blood-2007-03-081240. Epub 2007 May 17. Blood. 2007. PMID: 17510321 Free PMC article. Retracted. Clinical Trial. - Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth.
Huo J, Huang Y, Zheng Z, Tay XN, Mahfut FB, Zhang W, Lam KP, Yang Y, Xu S. Huo J, et al. Antib Ther. 2022 Jun 9;5(2):138-149. doi: 10.1093/abt/tbac012. eCollection 2022 Apr. Antib Ther. 2022. PMID: 35774245 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials